F119 - Adverse Drug Reactions: The Evidence and the Controversies
Monday, February 19; 9:00 AM - 11:00 AM
Following this course, the attendee should be able to:
- Discuss the balance of pros and cons regarding genetic testing for certain drugs and reactions
- Identify the steps that can help reduce risks to patients when informing them about therapy.
- Recognize risk and risk perception in pregnancy.
Prescribing medications is a very skilled task that is uniquely in the hands of physicians. Dermatologists may face changing science, exploding amounts of data, and skeptical patients. Legal risks also abound. In this sea of turmoil, it is important to share strategies to mitigate risks and learn from each other about lessons learned. This activity has been approved by the American Board of Dermatology (ABD) for up to 20 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org
- Martin, George M., MD: no financial relationships exist with commercial interests.
- Shear, Neil H., MD: AbbVie – A(H); Actelion – SP(H); Amgen – A(Grants/Research Funding); Biogen – A(H); Celgene Corporation – SP(H); Eli Lilly and Company – A(H); Janssen-Ortho Inc. – C(H), SP(H); Leo Pharma Inc – C(H); Novartis Pharmaceuticals Corp. – A(H), C(H); Sanofi/Regeneron – A(H); Valeant Pharmaceuticals International – A(H);
- Stratman, Erik Joseph, MD: no financial relationships exist with commercial interests.
- Wolverton, Stephen E., MD: Elsevier Inc. – Independent Contractor(OB);
Monday, February 19
Dr. Shear / Introduction
Dr. Martin / Risk Mitigation in Pregnancy
Dr. Shear / Genetic Testing: Why and Why Not?
Dr. Wolverton / Risk Mitigation and Litigation: Protect Thyself and Thy Patient
Dr. Stratman / Education About Risk Mitigation: Are We Doing Enough?
All faculty / Q&A